Skip to main content
. Author manuscript; available in PMC: 2006 Apr 5.
Published in final edited form as: Nat Med. 2005 May 22;11(7):774–779. doi: 10.1038/nm1255

Figure 6. Cannabinoid receptor antagonists inhibit ERK, c–fos, c–jun and NFATc1 activation in mouse osteoclasts.

Figure 6

a, Effects of the CB antagonist AM251 (5μM) on ERK phosphorylation as detected by western blot in vehicle (C) and RANKL (100ng/ml) treated mouse osteoclasts. The numbers refer to the time (min) after RANKL stimulation. MW is molecular weight marker and the size of the marker bands is indicated in kDa. b, Effects of AM251 on nuclear translocation and DNA binding of phospho NFATc1 in mouse osteoclasts treated with RANKL (100ng/ml) in the presence of vehicle or AM251 (2μM). c, Effects of AM251 on nuclear translocation and DNA binding of c–jun in mouse osteoclasts treated with RANKL (100ng/ml) in the presence of vehicle or AM251 (2μM). d, Effects of AM251 on DNA binding of c–fos in mouse osteoclasts treated with RANKL (100ng/ml) in the presence of vehicle or AM251 (2μM). Values are expressed as the change relative to vehicle treated cultures. Values in the bar charts are means and standard deviations. Significant differences between vehicle and RANKL treated cultures are indicated by: *** p<0.001; and differences between AM251 and vehicle treated cultures are indicated by: ## p<0.001. The results shown are representative of three independent experiments.